Status:
NOT_YET_RECRUITING
B2AD-Risk AFDAS Evolution of Burden of AF
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
Stroke
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Each year, 7.8 million people worldwide experience an ischemic stroke, often caused by atrial fibrillation (AF). AF is a major contributor to severe, disabling, and deadly strokes. About 20% to 30% of...
Detailed Description
Globally, 7.8 million individuals experience an ischemic stroke each year.1, 2 Atrial fibrillation (AF) is one of the most frequent causes of ischemic stroke, resulting in the most severe, disabling, ...
Eligibility Criteria
Inclusion
- Adult patients with cortical or subcortical, cryptogenic or non-cryptogenic acute ischemic stroke
- Any of the following types of AF:
- Paroxysmal AF known before stroke onset (KAF).
- Paroxysmal AF found on an admission or Emergency Department ECG (ECG-AFDAS)
- Paroxysmal AF found on 14-day Holter monitoring (PCM-AFDAS)
Exclusion
- Patients not willing to consent
- Permanent or persistent AF
- Allergy to iodinated contrast agents
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06589700
Start Date
May 1 2025
End Date
October 1 2026
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Heart & Brain Lab, Western University
London, Ontario, Canada, N6A 5A5